CHGCF - Chugai Pharmaceutical Co Ltd (CHGCF) on Q3 2020 Results - Earnings Call Transcript

Chugai Pharmaceutical Co Ltd (CHGCF) Q3 2020 Earnings Conference Call October 22, 2020, 05:00 ET Company Participants Toshiaki Itagaki - CFO Minoru Hirose - Department Manager, R&D Portfolio Management Dept. Shinji Hidaka - VP & Head, Marketing & Sales Division Conference Call Participants Kazuaki Hashiguchi - Daiwa Securities Hidemaru Yamaguchi - Citigroup Shinichiro Muraoka - Morgan Stanley Akinori Ueda - Goldman Sachs Group Fumiyoshi Sakai - Crédit Suisse Presentation Toshiaki Itagaki Good evening, ladies and gentlemen. This is Itagaki. I will start explaining the slides. Please look at the second page. It is a financial overview. In the cumulative third quarter, revenue was ¥576.5 billion. Operating income was ¥231.9 billion, and both sales and income grew by double digits, which reached record highs for the fourth consecutive year. Revenue performed generally well with a progress rate of 77.9% compared to the full year forecast. Operating income and quarterly income have

For further details see:

Chugai Pharmaceutical Co Ltd (CHGCF) on Q3 2020 Results - Earnings Call Transcript